Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) insider John Tilton sold 10,000 shares of Biohaven Pharmaceutical stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $50.11, for a total value of $501,100.00. Following the completion of the transaction, the insider now owns 10,000 shares of the company’s stock, valued at approximately $501,100. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
John Tilton also recently made the following trade(s):
- On Thursday, January 10th, John Tilton sold 10,500 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $37.67, for a total value of $395,535.00.
Shares of BHVN stock remained flat at $$50.10 on Friday. The stock had a trading volume of 1,308,001 shares, compared to its average volume of 432,098. The company has a market capitalization of $2.19 billion, a P/E ratio of -8.16 and a beta of 0.46. Biohaven Pharmaceutical Holding Co Ltd has a 12 month low of $16.50 and a 12 month high of $50.65.
Several equities analysts have issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price objective (up previously from $48.00) on shares of Biohaven Pharmaceutical in a research report on Monday, March 4th. Cantor Fitzgerald lifted their price objective on Biohaven Pharmaceutical to $82.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Zacks Investment Research downgraded Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th. ValuEngine upgraded Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Finally, Oppenheimer set a $63.00 target price on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Monday, December 10th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Biohaven Pharmaceutical has an average rating of “Buy” and a consensus price target of $53.00.
Hedge funds have recently added to or reduced their stakes in the company. Flinton Capital Management LLC bought a new stake in shares of Biohaven Pharmaceutical during the fourth quarter worth $42,000. Neuburgh Advisers LLC bought a new stake in shares of Biohaven Pharmaceutical during the fourth quarter worth $52,000. Tower Research Capital LLC TRC raised its position in shares of Biohaven Pharmaceutical by 602.4% during the third quarter. Tower Research Capital LLC TRC now owns 5,057 shares of the company’s stock worth $190,000 after acquiring an additional 4,337 shares during the last quarter. Legal & General Group Plc raised its position in shares of Biohaven Pharmaceutical by 14.1% during the fourth quarter. Legal & General Group Plc now owns 5,284 shares of the company’s stock worth $196,000 after acquiring an additional 652 shares during the last quarter. Finally, Shell Asset Management Co. bought a new stake in shares of Biohaven Pharmaceutical during the third quarter worth $205,000. Institutional investors own 97.60% of the company’s stock.
WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider John Tilton Sells 10,000 Shares” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2019/03/15/biohaven-pharmaceutical-holding-co-ltd-bhvn-insider-john-tilton-sells-10000-shares.html.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.
Featured Story: How to use beta for portfolio diversification
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.